OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W. Cescon, Peter Schmid, Hope S. Rugo, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 5, pp. 717-727
Closed Access | Times Cited: 7
David W. Cescon, Peter Schmid, Hope S. Rugo, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 5, pp. 717-727
Closed Access | Times Cited: 7
Showing 7 citing articles:
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1235-1235
Open Access | Times Cited: 2
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1235-1235
Open Access | Times Cited: 2
Integrating single-cell RNA-seq and bulk RNA-seq to explore prognostic value and immune landscapes of methionine metabolism-related signature in breast cancer
Yingchun Gao, Ziyu Feng, Hailong Zhao, et al.
Frontiers in Genetics (2025) Vol. 15
Open Access
Yingchun Gao, Ziyu Feng, Hailong Zhao, et al.
Frontiers in Genetics (2025) Vol. 15
Open Access
Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
P. De Santis, Martina Perrone, Chiara Guarini, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 232-250
Open Access | Times Cited: 2
P. De Santis, Martina Perrone, Chiara Guarini, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 232-250
Open Access | Times Cited: 2
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Matthew Monberg, Steve Keefe, Vassiliki Karantza, et al.
Oncology and Therapy (2024)
Open Access | Times Cited: 1
Matthew Monberg, Steve Keefe, Vassiliki Karantza, et al.
Oncology and Therapy (2024)
Open Access | Times Cited: 1
Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis
Jinquan Li, Xiaosheng Hu, Shanzhong Zhang
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access
Jinquan Li, Xiaosheng Hu, Shanzhong Zhang
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review
Sofia Georgopoulou, Joanne Droney, P.P. Jaganathan, et al.
Cancer Treatment Reviews (2024) Vol. 135, pp. 102862-102862
Open Access
Sofia Georgopoulou, Joanne Droney, P.P. Jaganathan, et al.
Cancer Treatment Reviews (2024) Vol. 135, pp. 102862-102862
Open Access
Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
Sabah Alaklabi, Arya Mariam Roy, Lubna N. Chaudhary, et al.
Exploration of Targeted Anti-tumor Therapy (2023) Vol. 4, Iss. 6, pp. 1301-1309
Open Access
Sabah Alaklabi, Arya Mariam Roy, Lubna N. Chaudhary, et al.
Exploration of Targeted Anti-tumor Therapy (2023) Vol. 4, Iss. 6, pp. 1301-1309
Open Access
